Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Medical Imaging
Published in: BMC Medical Imaging 1/2015

Open Access 01-12-2015 | Research article

A comparative study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and 99mTc-MDP whole-body bone scanning for imaging osteolytic bone metastases

Authors: Lin Zhang, Lihua Chen, Qiao Xie, Yongke Zhang, Lin Cheng, Haitao Li, Jian Wang

Published in: BMC Medical Imaging | Issue 1/2015

Login to get access

Abstract

Background

The objective of this study was to evaluate the feasibility and diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and 99mTc-methylenediphosphonate (MDP) whole-body bone scanning (BS) for the detection of osteolytic bone metastases.

Methods

Thirty-four patients with pathologically confirmed malignancies and suspected osteolytic bone metastases underwent 18F-FDG PET/CT and 99mTc-MDP whole-body BS within 30 days. The sensitivity, specificity, and accuracy with respect to the diagnosis of osteolytic bone metastases and bone lesions were compared between the two imaging methods.

Results

The sensitivity, specificity, and accuracy of 18F-FDG PET/CT for the diagnosis of osteolytic bone metastases were 94.3% (95% confidence interval [CI], 91.6–96.2%), 83.3% (95% CI, 43.6–96.9%), and 94.2% (95% CI, 91.5–96.1%), respectively. It was found that 99mTc-MDP whole-body BS could discriminate between patients with 50.2% (95% CI, 45.4–55.1%) sensitivity, 50.0% (95% CI, 18.8–81.2%) specificity, and 50.2% (95% CI, 45.5–55.1%) accuracy. 18F-FDG PET/CT achieved higher sensitivity, specificity, and accuracy in detecting osteolytic bone metastases than 99mTc-MDP whole-body BS (p<0.001).

Conclusions

F-FDG PET/CT has a higher diagnostic value than 99mTc-MDP whole-body BS in the detection of osteolytic bone metastases, especially in the vertebra.
Literature
1.
Basu D, Siegel BA, McDonald DJ, Nussenbaum B. Detection of occult bone metastases from head and neck squamous cell carcinoma: impact of positron emission tomography computed tomography with fluorodeoxyglucose F 18. Arch Otolaryngol Head Neck Surg. 2007;133:801–5.CrossRefPubMed
2.
Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC. Comparing whole body (18) F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol. 2002;128:325–8.CrossRefPubMed
3.
Liu NB, Zhu L, Li MH, Sun XR, Hu M, Huo ZW, et al. Diagnostic value of 18F-FDG PET/CT in comparison to bone scintigraphy, CT and 18F-FDG PET for the detection of bone metastasis. Asian Pac J Cancer Prev. 2013;14:3647–52.CrossRefPubMed
4.
Uchida K, Nakajima H, Miyazaki T, Tsuchida T, Hirai T, Sugita D, et al. (18) F-FDG PET/CT for Diagnosis of Osteosclerotic and Osteolytic Vertebral Metastatic Lesions: Comparison with Bone Scintigraphy. Asian Spine J. 2013;7:96–103.CrossRefPubMedPubMedCentral
5.
Kao CH, Hsieh JF, Tsai SC, Ho YJ, Yen RF. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res. 2000;20:2189–92.PubMed
6.
Kruger S, Buck AK, Mottaghy FM, Hasenkamp E, Pauls S, Schumann C, et al. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:1807–12.CrossRefPubMed
7.
Ozulker T, Kucukoz Uzun A, Ozulker F, Ozpacac T. Comparison of (18) F-FDG-PET/CT with (99m) Tc-MDP bone scintigraphy for the detection of bone metastases in cancer patients. Nucl Med Commun. 2010;31:597–603.PubMed
8.
Min JW, Um SW, Yim JJ, Yoo CG, Han SK, Shim YS, et al. The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer. J Korean Med Sci. 2009;24:275–80.CrossRefPubMedPubMedCentral
9.
Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.PubMed
10.
Kawaoka T, Aikata H, Takaki S, Uka K, Azakami T, Saneto H, et al. FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol Res. 2009;39:134–42.CrossRefPubMed
11.
Byun BH, Kong CB, Lim I, Kim BI, Choi CW, Song WS, et al. Comparison of (18) F-FDG PET/CT and (99 m) Tc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma. Skeletal Radiol. 2013;42:1673–81.CrossRefPubMed
12.
Volker T, Denecke T, Steffen I, Misch D, Schonberger S, Plotkin M, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 2007;25:5435–41.CrossRefPubMed
13.
Choi YJ, Shin YD, Kang YH, Lee MS, Lee MK, Cho BS, et al. The Effects of Preoperative (18) F-FDG PET/CT in Breast Cancer Patients in Comparison to the Conventional Imaging Study. J Breast Cancer. 2012;15:441–8.CrossRefPubMedPubMedCentral
14.
Montini KM, Tulchinsky M. False-positive bone metastases on PET/CT secondary to sarcoidosis in a patient with rectal cancer. Clin Nucl Med. 2012;37:307–10.CrossRefPubMed
15.
Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002;59:913–8.CrossRefPubMed
16.
Ito S, Kato K, Ikeda M, Iwano S, Makino N, Tadokoro M, et al. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med. 2007;48:889–95.CrossRefPubMed
17.
Hahn S, Heusner T, Kummel S, Koninger A, Nagarajah J, Muller S, et al. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. Acta Radiol. 2011;52:1009–14.CrossRefPubMed
18.
Kim MR, Roh JL, Kim JS, Choi SH, Nam SY, Kim SY. 18F-fluorodeoxyglucose-positron emission tomography and bone scintigraphy for detecting bone metastases in patients with malignancies of the upper aerodigestive tract. Oral Oncol. 2008;44:148–52.CrossRefPubMed
19.
Damle NA, Bal C, Bandopadhyaya GP, Kumar L, Kumar P, Malhotra A, et al. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan. Jpn J Radiol. 2013;31:262–9.CrossRefPubMed
20.
Shie P, Cardarelli R, Brandon D, Erdman W, Abdulrahim N. Meta-analysis: comparison of F-18 Fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med. 2008;33:97–101.CrossRefPubMed
21.
Riegger C, Herrmann J, Nagarajah J, Hecktor J, Kuemmel S, Otterbach F, et al. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging. 2012;39:852–63.CrossRefPubMed
22.
Iagaru A, Mittra E, Mosci C, Dick DW, Sathekge M, Prakash V, et al. Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial. J Nucl Med. 2013;54:176–83.CrossRefPubMed
23.
Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31:28–49.CrossRefPubMed
24.
Chang MC, Chen JH, Liang JA, Yang KT, Cheng KY, Kao CH. Accuracy of whole-body FDG-PET and FDG-PET/CT in M staging of nasopharyngeal carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2013;82:366–73.CrossRefPubMed
25.
Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32:1253–8.CrossRefPubMed
26.
Oh JR, Byun BH, Hong SP, Chong A, Kim J, Yoo SW, et al. Comparison of (1) (3) (1) I whole-body imaging, (1) (3) (1) I SPECT/CT, and (1) (8) F-FDG PET/CT in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38:1459–68.CrossRefPubMed
27.
Metadata
Title
A comparative study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and 99mTc-MDP whole-body bone scanning for imaging osteolytic bone metastases
Authors
Lin Zhang
Lihua Chen
Qiao Xie
Yongke Zhang
Lin Cheng
Haitao Li
Jian Wang
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Medical Imaging / Issue 1/2015
Electronic ISSN: 1471-2342
DOI
https://doi.org/10.1186/s12880-015-0047-2

Other articles of this Issue 1/2015

BMC Medical Imaging 1/2015 Go to the issue

Research article

A computer aided measurement method for unstable pelvic fractures based on standardized radiographs

Research article

Eigen-disfigurement model for simulating plausible facial disfigurement after reconstructive surgery

Correspondence

Voting for Image Scoring and Assessment (VISA) - theory and application of a 2 + 1 reader algorithm to improve accuracy of imaging endpoints in clinical trials

Research Article

Automated lesion detection on MRI scans using combined unsupervised and supervised methods

Case report

Hibernoma – two patients with a rare lipoid soft-tissue tumour

Research article

Osseous vitality in single photon emission computed tomography/computed tomography (SPECT/CT) after balloon tibioplasty of the tibial plateau: a case series